Tredegar Corporation: Q1 2009 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2009. Tredegar Corporation operates primarily in two segments: Film Products and Aluminum Extrusions. The company reported a significant net loss for the quarter, driven largely by a severe economic downturn impacting the aluminum extrusions market and a substantial non-cash goodwill impairment charge.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Net Sales | $153.1 million | $228.5 million |
| Net Income (Loss) | $(28.8) million | $3.1 million |
| Diluted EPS | $(0.85) | $0.09 |
| Operating Cash Flow | $33.3 million | $6.2 million |
| Cash and Equivalents | $53.3 million | $41.4 million |
| Total Debt | $9.6 million | $22.7 million (approx. based on prior period) |
| Shareholders' Equity | $387.6 million | $420.4 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 33.0% year-over-year. Film Products sales fell 20.8% due to lower volume and currency impacts. Aluminum Extrusions sales plummeted 50.5% due to a 36.8% volume decline driven by the recession in the non-residential construction sector.
- Goodwill Impairment: The company recognized a non-cash goodwill impairment charge of $30.6 million related to the Aluminum Extrusions reporting unit. This charge represented the entire goodwill balance for that segment.
- Profitability: The company swung from a net income of $3.1 million in Q1 2008 to a net loss of $28.8 million in Q1 2009. Operating profit from ongoing operations in Aluminum Extrusions turned negative ($1.8 million loss) compared to a $1.5 million profit in the prior year.
- Restructuring: The company incurred $1.6 million in pretax severance and restructuring costs, including a workforce reduction of approximately 50 people in Film Products and further reductions in Aluminum Extrusions.
- Debt Reduction: Long-term debt decreased significantly by $13.1 million as the company utilized strong operating cash flows to pay down borrowings under its revolving credit facility.
Outlook, Risks, and Management Commentary
- Market Conditions: Management cites "extremely challenging market conditions" and a third year of recession in the aluminum extrusions industry. Order rates have deteriorated, and customer inventory adjustments continue to impact volume.
- Cost Reduction: The company is aggressively focused on controlling variable costs and reducing fixed costs. The Q1 2009 workforce reductions in Film Products are expected to save $2.5 million on an annualized basis.
- Liquidity: Despite the loss, operating cash flow was strong at $33.3 million. The company maintains a $300 million revolving credit facility with $235.2 million available. Management believes current cash balances and operating cash flows are sufficient to meet working capital, capital expenditure, and dividend requirements.
- Capital Expenditures: Projected capital expenditures for 2009 are approximately $41 million ($20 million for Film Products and $21 million for Aluminum Extrusions), including a major expansion project in Carthage, Tennessee.
- Risks: Key risks include volatility in raw material prices (resin, aluminum, natural gas), foreign currency fluctuations, and the inability to pass through cost increases to customers. The company also faces uncertainty regarding the timing of an economic recovery.
Investor Verification Checklist
- Goodwill Impairment Validity: Verify the assumptions used in the discounted cash flow analysis that led to the $30.6 million write-off in Aluminum Extrusions.
- Volume Recovery: Monitor order rates and shipment volumes in the non-residential construction sector to gauge the sustainability of the 36.8% volume decline.
- Raw Material Hedging: Review the effectiveness of aluminum futures hedging strategies given the volatility in LME aluminum prices and the timing differences in revenue recognition.
- Debt Covenants: Confirm continued compliance with the revolving credit agreement covenants, specifically the leverage ratio (currently 0.24x) and interest coverage ratio (30.40x).
- Investment Valuation: Assess the fair value of the $13.1 million investment in the privately held drug delivery company, which relies on Level 3 inputs and has no current product sales.